131 results
Page 3 of 7
8-K
EX-99.1
ygonu4hbu25k
5 Apr 21
Invitae Announces $1.15 Billion Investment Supporting Ongoing Growth Initiatives
4:13pm
S-3ASR
ubwnm5lo0t1jev
26 Feb 21
Automatic shelf registration
12:00am
S-3ASR
4t7clzm9z zeft0p8a
26 Feb 21
Automatic shelf registration
12:00am
8-K
EX-99.1
02kv75qgoofe71
17 Feb 21
Invitae Reports $279.6 Million in Annual Revenue Driven by 659,000 in Billable Volume in 2020
4:09pm
8-K
EX-99.1
a3ip59 gxwxc4
26 Jan 21
Invitae Announces Pricing of Public Offering of Common Stock
4:12pm
8-K
EX-99.2
iqo7ngqt zelw
26 Jan 21
Invitae Announces Pricing of Public Offering of Common Stock
4:12pm
424B5
hzrzw
25 Jan 21
Prospectus supplement for primary offering
4:02pm
424B5
2p0hv 63p
20 Jan 21
Prospectus supplement for primary offering
4:24pm
8-K
EX-99.1
by0ioj9zs96
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm
8-K
EX-99.2
dqdtb6c gp0x
20 Jan 21
Invitae Announces Proposed Public Offering of Common Stock
4:10pm
8-K
EX-99.2
vdq9u564
12 Jan 21
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume
6:06am
8-K
EX-99.1
zobo62onx3iqfaqbf
12 Jan 21
Invitae Reports Preliminary 2020 Financial Results of More Than $278 Million in Revenue and More Than 655,000 in Billable Volume
6:06am
424B7
8r439n
5 Nov 20
Prospectus with selling stockholder info
5:27pm
8-K
EX-99.1
gxaf950 93yf
5 Nov 20
Invitae Reports $68.7 Million in Revenue Driven by 170,000 Samples Accessioned in the Third Quarter of 2020
4:24pm
8-K
EX-99.1
46cldirjkgg
5 Oct 20
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide
4:17pm
424B3
9dyi3lkaf19hk1ht
28 Aug 20
Prospectus supplement
4:31pm